Pyxis Oncology Q3 net loss $22.0M; cash $77.7M, runway into H2 2026

Pyxis Oncology, Inc.

2025-Q3 EPS reported -$0.99 vs consensus -$0.35 ▼ miss (-186.7%)

Net loss $22.0M ($0.35/share) for Q3 2025, vs $21.2M loss in Q3 2024.
Cash and equivalents $77.7M; expected to fund operations into H2 2026.
R&D expenses $17.8M; increase in MICVO costs offset by pause of PYX-106 program.
Preliminary Phase 1 data for micvotabart pelidotin (MICVO) in HNSCC expected in Q4 2025.
Translational data presented at ESMO and AACR-NCI-EORTC on MICVO's three mechanisms of action.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.